Acalabrutinib and Zanubrutinib Both Best Ibrutinib in Real-World Safety and Efficacy CLL/SLL Outcomes
Lower Tumor Burden Associated With Improved ORR With Liso-Cel in R/R CLL/SLL
Dr Samarasinghe on the Feasibility of First-Line Blinatumomab in Down Syndrome B-ALL
Dr Trudel on Results From the DREAMM-7 Trial of BVd in R/R Multiple Myeloma